Cancer immunotherapy has brought a paradigm shift in cancer treatment. It uses the immune system’s strength to treat cancers. However, next-generation cancer immunotherapies have yet to reach their full potential. Poor throughput of functional screens that can only evaluate a few thousand antibodies is a limitation.
Droplet microfluidic technology enables exceptional throughput in cell research and screening at the single-cell level. For example, the examination of millions of plasma cells for antibodies linked to vaccinations or cancer targets thanks to the intricacy of the microfluidic droplet technique. Screening for functional antibodies, on the other hand, desperately needs improvement.
Researchers have devised a technology platform. It allows them to screen for antibody binding, agonistic activity, bispecific antibody activities simultaneously. This approach combines the strength of an autocrine-based lentiviral transduction system with the microfluidic droplet technique. This streamlined method offers a quick and impartial discovery of active antibodies with significantly higher throughput and accuracy.